Maze Therapeutics, Inc. (MAZE)
22.52
-0.92
(-3.92%)
USD |
NASDAQ |
Sep 18, 16:00
22.61
+0.09
(+0.40%)
Pre-Market: 20:00
Maze Therapeutics Shareholders Equity (Quarterly) : 453.12M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 453.12M |
| March 31, 2026 | 341.70M |
| December 31, 2025 | 354.97M |
| September 30, 2025 | 379.44M |
| June 30, 2025 | 262.24M |
| Date | Value |
|---|---|
| March 31, 2025 | 292.07M |
| December 31, 2024 | 196.90M |
| September 30, 2024 | 99.37M |
| March 31, 2024 | |
| December 31, 2023 | 10.05M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 531.62M |
| Total Liabilities (Quarterly) | 78.50M |
| Debt to Equity Ratio | 0.1333 |
| Current Ratio | 18.31 |
| Net Debt Paydown Yield | -0.42% |